Ascendis Pharma A/S ASND · Stock Open Ascendis Pharma A/S in new tab
Ascendis Pharma A/S Analysis (ASND)
Is Ascendis Pharma A/S a good investment? Ascendis Pharma A/S (ASND) is currently trading at 274.50 USD. Market analysts have a consensus price target of 291.75 USD. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 30.59. This high multiple suggests investors have priced in significant future growth expectations.
Earnings Schedule: Ascendis Pharma A/S is expected to release its next earnings report on Aug. 6, 2026. The market consensus estimate for Forward EPS is 10.74.
Investor FAQ
Does Ascendis Pharma A/S pay a dividend?
No, it does not currently pay a dividend.
What asset class is Ascendis Pharma A/S?
Ascendis Pharma A/S is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Aug. 6, 2026. The company currently has a trailing EPS of 8.62.
Company Profile
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
Community Discussion